Home › Compound Library › CJC-1295 (no DAC) / Mod GRF 1-29

CJC-1295 (no DAC) / Mod GRF 1-29

Peptidesubcutaneous · inferred

Modified growth hormone-releasing factor (1-29) with amino acid substitutions at positions 2, 8, 15, and 27 to resist DPP-IV cleavage. Half-life ~30 minutes (vs 7 min for native GHRH). Produces a pulsatile GH release mimicking natural physiology. Often combined with ipamorelin for synergistic GH release. Dosed 100 mcg SC 2-3x daily.

Projected serum levels — 100 mcg (≈ 0.10 mg), twice daily

CJC-1295 (no DAC) / Mod GRF 1-29
CJC-1295 (no DAC) / Mod GRF 1-29 modeled serum levels, 100 mcg (≈ 0.10 mg) twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1
CJC-1295 (no DAC) / Mod GRF 1-29 modeled serum levels with a loading dose of 164 mcg, then 100 mcg (≈ 0.10 mg) twice daily The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 100 mcg (≈ 0.10 mg) twice daily (subcutaneous).

Loading schedule: 164 mcg on day 1, then 100 mcg (≈ 0.10 mg) twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~1 days: peak ≈ 0.064 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
29 min
Common dose
100 mcg (≈ 0.10 mg)
Suggested maximum
300 mcg/day
Reference dose range
50–300 mcg (single dose)
Suggested cadence
twice daily

Documented interactions

  • watch
    CJC-1295 DAC + CJC-1295 (no DAC) / Mod GRF 1-29 Stacked effects

    CJC-1295 DAC and CJC-1295 (no DAC) / Mod GRF 1-29 both push the ghrh receptor in the same direction.

  • watch
    Tesamorelin (Egrifta) + CJC-1295 (no DAC) / Mod GRF 1-29 Stacked effects

    CJC-1295 (no DAC) / Mod GRF 1-29 and Tesamorelin (Egrifta) both push the ghrh receptor in the same direction.

Serum checks 2 modeled interaction pairings for cjc-1295 (no dac) / mod grf 1-29 across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Teichman SL et al. · Journal of Clinical Endocrinology & Metabolism, 2006 DOI

    Key clinical study of CJC-1295 showing dose-dependent GH increases of 2-10 fold lasting 6+ days and IGF-I increases of 1.5-3 fold lasting 9-11 days after single injection. The DAC version had half-life of 5.8-8.1 days.

  2. Growth hormone secretagogues: history, mechanism of action, and clinical development Ishida J et al. · JCSM Rapid Communications, 2020 DOI

    Review covering GHRH analogs including CJC-1295 variants, their mechanisms of action, and clinical development for GH deficiency and anti-aging applications.

  3. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J · Endocrinology, 1985 DOI

    This citation reports an animal study involving related analogue evidence, not direct evidence for CJC-1295 (no DAC) / Mod GRF 1-29. The study compared growth-hormone-releasing factor analogues and does not establish…

3 published studies referenced in the app, each with a plain-language summary.